NCT06487624View on ClinicalTrials.gov

An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 2, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Advanced Solid TumorRefractory Hodgkin Lymphoma
Interventions
DRUG

HCB301

HCB301 administered via. intravenous (IV) infusion.

Trial Locations (1)

29605

RECRUITING

Prisma Health-Upstate, Greenville

Sponsors
All Listed Sponsors
lead

FBD Biologics Limited

INDUSTRY

NCT06487624 - An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors | Biotech Hunter | Biotech Hunter